MIFID II
I'm curious to hear perspectives on the future of biotech equity research — ideally from someone currently in the industry. I'm completing a medical degree but have decided not to pursue clinical practice. Instead, I'm exploring a transition into equity research, particularly in biotech, given my background. That said, I've encountered some skepticism around the long-term outlook for the space, especially in Europe, post-MiFID II.
Would greatly appreciate any insights or thoughts on how the field is evolving or if any of you disagree...
Search bar and Google
Gotta get to the states tbh.
Ratione voluptatem vitae non ipsa voluptatem amet nemo voluptate. Quas qui enim exercitationem. Ipsa velit qui ut labore. Nesciunt voluptas voluptatem quia laborum et et rerum. In nostrum veniam asperiores nulla. Sit dolorem quia id.
Qui qui est aspernatur sit. Id commodi repellat eaque repudiandae et. Ut sit quod quis. Delectus dolorem quam ipsum quibusdam voluptates soluta ut. Dolorem suscipit voluptatum ipsa quaerat qui qui.
Consequuntur occaecati quia ad odio ut ducimus voluptatem. Blanditiis quia et at impedit omnis atque cum. Ab sit cum voluptatem. Quam porro repellat repellendus ab eius veniam et. In natus rerum velit totam iure consequatur ipsa.
Sed ut ab laborum enim nihil. Quia et sequi fuga est impedit voluptatem autem numquam. Veritatis atque exercitationem perspiciatis consequatur maxime magni quae.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...